Anticancer Drugs News

News

Infection risk not increased with alemtuzumab : The Lancet Oncology
www.thelancet.com | 5 hours 46 minutes ago
Infection risk not increased with alemtuzumab. By - Bryant Furlow

Eisai Company Ltd s Cancer Drug Reverses
www.biospace.com | Feb 10, 2012
In what is seen as a major breakthrough in finding a cure for Alzheimer's, neuroscientists at Case Western Reserve University School of Medicine, Ohio,

Roche Holding's CEO Discusses Q4 2011 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com | Feb 10, 2012
< p > Roche Holding Ltd. ( < a href='http://seekingalpha.com/symbol/rhhby.pk' title='Roche Hldg Ltd Spons' > RHHBY.PK < /a > ) < /p > < p > Q4 2011 Earnings Call < /p > < p > February 01, 2012 01:00 am ET < /p > < p > < strong > Executives < /strong > < /p > < p > Severin Schwan – Chief Executive

Protein Compounds Dominate Angiogenesis Cancer Drug Pipeline Says Report | PRLog
www.prlog.org | Feb 9, 2012
Protein Compounds Dominate Angiogenesis Cancer Drug Pipeline Says Report. Piribo, the online destination for Pharma intelligence, has added a new report. - PR11794758

FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications {– Study met
www.takeda.com | Feb 9, 2012
CAMBRIDGE, Mass., January 23, 2012–Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE^®

Popular Colorectal Cancer Drug May Cause Permanent Nerve Damage - 09/27/2011
www.hopkinsmedicine.org | Jan 27, 2012
Oxaliplatin, a platinum-based anticancer drug that’s made enormous headway in recent years against colorectal cancer, appears to cause nerve damage that may be permanent and worsens even months after treatment ends. The chemotherapy side effect, described by Johns Hopkins researchers in the

FDA Notifies Genentech of Violations at Avastin Plant - - BioPharm International
biopharminternational.findpharma.com | Jan 6, 2012
On Sept. 27, 2011, FDA sent Genentech a Form 483 listing several violations at the company?s South San Francisco, California, plant. The violations included problems with investigations into batch failures, inappropriate equipment design, and insufficient protection against contamination. FDA

FDA Removes Avastin Breast Cancer Indication - Pharmaceutical Technology
pharmtech.findpharma.com | Dec 16, 2011
The breast cancer indication for Avastin has been revoked after FDA Commissioner Margaret A. Hamburg concluded that the drug has not been shown to be safe and effective for this use.

FDA blow for blockbuster Roche drug - FT.com
www.ft.com | Nov 18, 2011
The US Food and Drug Administration has revoked approval for Roche’s blockbuster drug Avastin to treat breast cancer, dealing a blow to the company and disappointing health groups that have argued the drug has saved lives. Margaret Hamburg, FDA

Abbott to Present Broad Spectrum of Compelling Data for HUMIRA® (Adalimumab) at American College of
www.abbott.com | Nov 2, 2011
Abbott to Present Broad Spectrum of Compelling Data for HUMIRA® (Adalimumab) at American College of Rheumatology Annual Scientific Meeting